1 Year of Palsonify and What Switching From Acromegaly Injections to a Pill Involves

September 25th marks 1 year since the FDA approved the first once-daily pill for acromegaly. That anniversary matters more than most drug birthdays, because for most of the last 4 decades, keeping this disease controlled has meant needles, most commonly a thick depot injection every 28 days, delivered at a clinic or by a home nurse, into muscle or deep under the skin. People built their calendars around it. Vacations got scheduled against injection dates. Then Palsonify (paltusotine) showed up as a tablet you swallow once a day, and the question every acromegaly patient has been working through since is whether, and how, to switch.

This post is the 1-year check-in: what the switch actually involves in practice, what the first 12 months of real-world uptake reveal, what it costs, and the FDA decision on December 18th that will shape the other half of this story. If you are newly diagnosed and still sorting out what acromegaly even is, start with our disease guide and come back.

What the Palsonify Approval Changed on September 25th, 2025

On September 25th, 2025, the FDA approved Palsonify as a first-line treatment for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option (Crinetics, 2025). The active ingredient, paltusotine, is a nonpeptide somatostatin receptor type 2 agonist, which is a chemist's way of saying it hits the same receptor the injectable drugs hit, using a small molecule stable enough to survive your stomach. That stability is the whole trick. Octreotide and lanreotide, the injectable standards, are peptides that digestion would shred, which is why they were built as monthly depots in the first place. One oral workaround already existed: Mycapssa, a 2020 capsule that smuggles the octreotide peptide through the gut with an absorption enhancer, taken twice a day. Palsonify is different chemistry, a small molecule designed for the mouth from the start, and the first acromegaly medicine you take just once a day by swallowing it.

The approval rested on 2 Phase 3 trials with a detail worth pausing on: one of them, PATHFNDR-1, was designed entirely around the switch. Every participant was an acromegaly patient already controlled on monthly octreotide LAR or lanreotide depot injections, the same situation most treated patients are in today. Researchers moved them to the daily tablet or to placebo and watched IGF-1, the blood marker endocrinologists steer by. Among patients switched to Palsonify, 83.3% held their IGF-1 in range through week 36. Among those switched to placebo, 3.6% did (J Clin Endocrinol Metab, 2025).

The second trial, PATHFNDR-2, tested the harder question: whether the pill can control active disease on its own. Its 111 participants had uncontrolled acromegaly, most of them starting medical therapy from scratch after surgery alone. After 24 weeks, 55.6% of patients on paltusotine reached a normal IGF-1 against 5.3% on placebo, and in the subgroup who had washed out of injections beforehand, 92.9% reached normal IGF-1 against 13.3% (J Endocr Soc, 2024). Symptom scores improved on the pill while they worsened on placebo, most of the IGF-1 drop arrived within the first 2 to 4 weeks, and no serious adverse events occurred in the paltusotine group.

The trials also measured something injections never captured well: symptoms, tracked daily through the Acromegaly Symptom Diary, a patient-reported tool covering headaches, joint pain, sweating, fatigue, weakness, swelling, and numbness or tingling. Many patients on monthly depots know the end-of-cycle pattern, where symptoms creep back in the final week before the next injection. A follow-up analysis published in July 2026 put numbers to that pattern. Among 22 PATHFNDR-1 participants with enough diary data to compare, breakthrough symptom flares fell from 30.2% of days during the screening period, while they were still on their injections, to 6.2% of days after switching to the daily tablet, a drop the authors report as statistically significant even though this was a post hoc analysis of a small group (Pituitary, 2026). The likely mechanism is steadiness: a once-daily pill reaches stable drug levels within a week and holds them, where a depot peaks and fades across the month.

“For people living with acromegaly, treatment once meant burdensome injections, breakthrough symptoms, and lifestyle sacrifices just to stay on track.”

Jill Sisco, President of Acromegaly Community, on the day of the approval

What Patients Told the FDA About Life on Injections

Sisco's organization did more than comment on approval day. The best record of what the injection era felt like comes from the community itself: on January 21st, 2021, Acromegaly Community convened an externally led Patient-Focused Drug Development meeting, a formal FDA-model forum where patients speak directly to agency officials and drug developers. Sisco organized the meeting, co-authored the resulting Voice of the Patient report, and submitted it to the FDA's metabolism and endocrinology drug review division (Acromegaly Community, 2021). Read today, the 93-page report is a preview of everything this past year has been about.

Patients described injections that hurt, that bruise, and that leave lumps of scar tissue after years of rotating among the approved injection sites. One woman, more than a decade into a 3-week Sandostatin LAR cycle, told the meeting that injecting into old scar tissue had become like trying to inject into a cork, and that some visits took 3 needle attempts before the medication went in. Others described the end-of-cycle wean, the final week before the next shot when the drug runs low: flu-like body aches, brain fog, a slight temperature, a week deliberately kept free of plans. A patient in her early 30s said she knew her injection was due because she could feel it in her knees. Several asked outright for oral options, for implants, for patches, for anything that did not involve a needle and did not come with breakthrough symptoms.

The logistics testimony is its own genre inside the report. Several of these medicines have to be kept refrigerated, some individually mixed before use, which turns a camping trip, a shift-work schedule, or an overnight drive into a cold-chain planning exercise. One patient described building every vacation around injection day so travel would never interfere with the shot. Another counted the packaging waste of single-dose boxes as one more small indignity. Patients asked for a version of their medicine that did not need a fridge, did not need mixing, did not need a nurse. A tablet in a bottle answers nearly all of that at once, though in fairness it swaps in a constraint of its own, the empty stomach rule covered below.

The report's third major finding sits upstream of all of it: most people with acromegaly are diagnosed years after their first symptoms, after rounds of being told the fatigue is stress, the joint pain is age, the headaches are nothing. One patient, diagnosed at 62, was told her tumor had likely been growing for 20 years. Others described connecting the dots themselves online after doctors stopped looking. That delay is why we built our Symptom Finder, and it is why symptom-focused evidence matters so much in this disease: by the time treatment starts, patients have usually been explaining these symptoms to skeptical audiences for a decade.

The report's polling numbers explain why a pill mattered before one existed. Asked whether their disease was controlled, patients revealed a wide gap between biochemical control, the IGF-1 number doctors watch, and symptomatic control, the life patients actually live. Asked to rank their top priorities for future drug development, they put a treatment for fatigue and muscle weakness first at 57% and relief for joint problems second at 49%. Better IGF-1 control came third, at 44%. The number their disease is managed by, the number their treatments are approved on, ranked below how they feel getting through a day. One patient put the stakes plainly: most days, she questioned whether taking the shot was worth it at all.

Hold that 2021 report next to the 2026 data above and the through line is hard to miss. The symptom diary used in the PATHFNDR trials was developed in accordance with FDA guidance and built around symptoms that separate patient research had already shown matter most to people with acromegaly, filled out daily rather than recalled at quarterly appointments. The breakthrough-flare analysis, 30.2% of days down to 6.2%, reads like a direct answer to the report's central complaint. None of that happened on its own. A patient-focused drug development meeting takes years of unglamorous organizing: recruiting panelists, running live polls, collecting testimony from patients too sick to call in, and distilling all of it into a report regulators can actually use. Sisco and her volunteer-run nonprofit did that work for a disease community of a few thousand people, and the PATHFNDR program was judged partly on the standard they helped set. In her framing, the approval reflects a community whose voices have been heard in shaping the next generation of acromegaly care. The evidence standard moved toward the patients, and the first drug judged partly on their terms is the one turning 1 this month. When patient advocacy works, this is what it looks like: years of listening, a 93-page report, and a trial program that measured what patients said mattered.

What Switching From Injections to the Pill Involves

Palsonify became available in the US in early October 2025 (Crinetics, 2025). A year in, the switching process is well mapped. It is not as simple as dropping off a new prescription, and the friction points are worth knowing before your next endocrinology appointment.

A specialty pharmacy, not your corner drugstore

Palsonify moves through limited distribution: 2 specialty pharmacies, Orsini and Biologics by McKesson, plus some pituitary treatment centers. Starting requires an enrollment form signed by both you and your prescriber, routed through the CrinetiCARE support program. Expect the gap between prescription and first tablet to run days to weeks, a pattern we mapped across rare disease drugs in our approval-to-first-dose guide.

The empty stomach rule

The label says to take Palsonify at least 6 hours after your last meal and at least 1 hour before your next one. In practice most people take it right after waking, having fasted overnight, then hold breakfast for an hour. If your mornings cannot absorb that rhythm, say so before you switch, because dosing with food cuts absorption.

A heartburn medication audit

Proton pump inhibitors like omeprazole reduce the amount of paltusotine your body absorbs. Your dose may need to go up if you stay on one, and the label says to avoid PPIs entirely at the 60 mg dose. Bring your full list of stomach medications, including anything over the counter, to the switching conversation.

A starting dose your doctor tunes

Treatment starts at 40 mg once daily. Your endocrinologist can raise it to 60 mg if IGF-1 stays above target, or lower it if side effects push back. The most common early side effects are diarrhea, abdominal pain, nausea, and decreased appetite, and in the trials most of the effect on IGF-1 appeared within the first month, so early labs tell you quickly where you stand.

The same monitoring you already know

IGF-1 labs still anchor everything, and your endocrinologist will also keep an eye on blood glucose, heart rate, thyroid function, and vitamin B12, plus gallbladder symptoms, the same watch list the injectable somatostatin drugs carry.

Insurance homework up front

At this price, prior authorization is close to certain. CrinetiCARE runs benefit verification and financial assistance before the first shipment, and the numbers below suggest payers are increasingly saying yes.

One more thing the first year made clear: timing the handoff from your last depot injection to your first tablet is a decision your endocrinologist makes deliberately, since the old drug is still washing out of the depot while the new one starts. Do not improvise that transition on your own.

The $290,000 Question, What Palsonify Costs and Who Pays

Palsonify launched at a wholesale list price of about $290,000 per year, more than 3 times the price of the injectable somatostatin drugs it competes with, which run near $80,000 (STAT News, 2025). List price is not what patients pay, and for a rare disease drug the number that matters more is whether insurers cover it. The early answer is mostly yes: by the end of the first quarter of 2026, about 70% of patients on Palsonify were on reimbursed therapy, with coverage expanding as payers added the drug to their formularies (Crinetics, 2026).

The uptake curve tells the rest of the story. The launch quarter brought in $5.4 million. The first full quarter of 2026 nearly doubled that, with 232 new patient enrollment forms and 263 unique prescribers writing the drug within the first 2 quarters (Crinetics, 2026). For a disease diagnosed in about 3,000 Americans a year, with an estimated 25,000 to 30,000 living with it, that early uptake amounts to a visible share of the whole treated population. Crinetics itself was acquired along the way: it is now a Vertex Pharmaceuticals company, which changes nothing about the drug and possibly a lot about how hard it gets marketed.

If the insurance maze around a brand-new specialty drug is unfamiliar territory, our guide to what happens between FDA approval and your first dose walks through specialty pharmacies, prior authorization, and why the calendar gap varies so much from drug to drug.

The Injection Is Not Done Yet

The needle side of acromegaly care is evolving too, and it deserves a fair hearing, because switching to a pill is not right for everyone. Some patients are rock-stable on a monthly depot and prefer 12 treatment moments a year over 365. Some take a proton pump inhibitor they cannot give up. Some simply do not want to re-run the trial-and-error of finding a controlling dose. For them, the interesting development is Oclaiz, an octreotide subcutaneous depot from Camurus that patients inject themselves once a month with an autoinjector pen, no clinic visit required. UK regulators approved it in August 2025 under the name Oczyesa (Camurus, 2025). The FDA rejected the US application in June 2026 with a complete response letter, Camurus resubmitted, and a new decision is due by December 18th, 2026 (Camurus, 2026).

We are tracking that decision day by day on our Oclaiz countdown page, alongside every other pending rare disease decision on the FDA calendar. If it clears, US acromegaly patients will have gone from zero convenient options to 2 fundamentally different ones, a daily tablet and a self-administered monthly pen, inside 15 months.

Behind those 2 sit more contenders. Debio 4126, a long-acting octreotide aimed at stretching the dosing interval even further, is recruiting a Phase 3 trial for patients previously treated with somatostatin analogs, and MAR002, an early-stage growth hormone receptor antagonist antibody, has opened a first trial with US sites. Both are listed with every other recruiting study on our acromegaly trials page. For a disease this rare, 4 companies competing on convenience at once is remarkable, and it is what patients asked the FDA to make room for in 2021.

Palsonify itself is spreading beyond the US. The European Commission approved it in April 2026 for all 27 EU member states plus 3 more European Economic Area countries, with first launches planned in Germany and Austria (Crinetics, 2026). Applications are under review in Japan and Brazil. The pill era in acromegaly is going global on roughly a 1-year lag behind the US.

The molecule has a second act underway too. Paltusotine is in a pivotal Phase 3 trial called CAREFNDR for carcinoid syndrome, the hormone-driven flushing and diarrhea that comes with certain neuroendocrine tumors, a condition also treated today with the same monthly somatostatin injections. Phase 2 results showed rapid, sustained reductions in flushing episodes and bowel movement frequency (Crinetics, 2025). If that program succeeds, the same needle-to-tablet story will replay in a second disease community, this time with a playbook.

Questions Acromegaly Patients Are Asking About the Switch

1 year ago the acromegaly community was counting down to an approval. This September the countdown is quieter: a first anniversary that has already changed the daily texture of the disease for the patients who switched first, with thousands more deciding, appointment by appointment, whether the pill is for them. We will be watching December 18th the same way we watched September 25th. If you want the next acromegaly decision in your inbox the day it lands, the signup below does exactly that.